CymaBay Therapeutics
Stock Forecast, Prediction & Price Target
CymaBay Therapeutics Financial Estimates
CymaBay Therapeutics Revenue Estimates
CymaBay Therapeutics EBITDA Estimates
CymaBay Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $31.07M 0% | Avg: $115.30M Low: $12.92M High: $281.02M avg. 271.07% | Avg: $274.08M Low: $45.04M High: $596.32M avg. 137.69% | Avg: $457.10M Low: $75.12M High: $994.53M avg. 66.77% | Avg: $695.08M Low: $114.22M High: $1.51B avg. 52.06% |
Net Income
% change YoY
| $-92.58M N/A | $-118.89M -28.41% | $-105.37M 11.37% | Avg: $-158.32M Low: $-267.63M High: $-73.28M avg. -50.25% | Avg: $-45.83M Low: $-81.77M High: $21.24M avg. 71.04% | Avg: $134.70M Low: $-11.63M High: $340.58M avg. 393.85% | Avg: $280.91M Low: $-24.25M High: $710.26M avg. 108.54% |
EBITDA
% change YoY
| $-86.72M N/A | $-91.09M -5.03% | $-85.74M 5.87% | Avg: $69.18M Low: $7.75M High: $168.61M avg. 180.68% | Avg: $164.44M Low: $27.02M High: $357.79M avg. 137.69% | Avg: $274.26M Low: $45.07M High: $596.72M avg. 66.77% | Avg: $417.04M Low: $68.53M High: $907.38M avg. 52.06% |
EPS
% change YoY
| -$1.3 N/A | -$1.35 -3.84% | -$0.99 26.66% | Avg: -$1.21 Low: -$2.52 High: -$0.69 avg. -22.04% | Avg: -$0.36 Low: -$0.77 High: $0.2 avg. 70.20% | Avg: $1.27 Low: -$0.11 High: $3.21 avg. 452.31% | Avg: $2.65 Low: -$0.23 High: $6.69 avg. 108.54% |
Operating Expenses
% change YoY
| $87.58M N/A | $93.11M 6.31% | $132.07M 41.84% | Avg: $130.80M Low: $14.66M High: $318.78M avg. -0.96% | Avg: $310.91M Low: $51.09M High: $676.46M avg. 137.69% | Avg: $518.54M Low: $85.21M High: $1.12B avg. 66.77% | Avg: $788.49M Low: $129.58M High: $1.71B avg. 52.06% |
FAQ
What is CymaBay Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 130.79% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -267.63M, average is -158.32M and high is -73.28M.
What is CymaBay Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 131.90% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $12.92M, average is $115.30M and high is $281.02M.
What is CymaBay Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 152.25% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$2.52, average is -$1.21 and high is $-0.69.